1 21 4

Overview

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

Learn more

Partnering


Jan. '13 - Strategic alliance with Gilead on four DARTs.
Sep. '12 - Collaboration with Servier on multiple oncology DARTs.
Dec.  '11 - Collaboration with Servier on MGA271.
Oct. '10 - Global DART partnerships with Pfizer and Boehringer Ingelheim. Learn more

News & Media

Recent Press Releases

October 10, 2013 | Press Release
MacroGenics Announces Pricing of Initial Public Offering

September 19, 2013 | Press Release
MacroGenics' Board of Directors Elects Paulo F. Costa as Chairman

August 20, 2013 | Press Release
MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271

> See all Press Releases

Recent News Articles

February 19, 2013 | BioWorld
Bispecific Antibodies Capturing Great Deal of Industry Interest

January 07, 2013 | Washington Business Journal
MacroGenics Could Get $1B Payday

January 07, 2013 | Dow Jones Business News
MacroGenics Strikes Another Deal; Gilead Alliance Could Yield More Than $1 Billion

> See all News

> Email Alerts: Stay on top of MacroGenics developments.

> Media Kit: Download corporate fact sheet and technology platform overview documents as well as corporate logos.